/ / / Tab 3

Review Article

miR-19 Is a Potential Clinical Biomarker for Gastrointestinal Malignancy: A Systematic Review and Meta-analysis

Table 3

Subgroup analyses were stratified on the basis of histology.


	Stage		Grade		Lymph node metastasis		Distant metastasis

Colorectal cancer		OR (95% CI)		OR (95% CI)		OR (95% CI)		OR (95% CI)
Colorectal cancer	6	2.74 (1.45, 5.18)	3	1.36 (0.74, 2.51)	7	1.89 (0.99, 3.63)	8	2.02 (0.77, 5.32)
Gastric cancer		OR (95% CI)		OR (95% CI)		OR (95% CI)		OR (95% CI)
Gastric cancer	2	0.42 (0.17, 1.04)	2	0.31 (0.14, 0.70)	3	0.46 (0.14, 1.52)	1	0.31 (0.10, 0.97)
Esophagus cancer		OR (95% CI)		OR (95% CI)		OR (95% CI)		OR (95% CI)
Esophagus cancer	1	1.72 (0.95, 3.12)	1	1.65 (0.86, 3.16)	1	1.87 (0.91, 3.85)	None	None
Liver cancer		OR (95% CI)		OR (95% CI)		OR (95% CI)		OR (95% CI)
Liver cancer	4	0.66 (0.18, 2.45)	4	0.80 (0.47, 1.35)	1	4.75 (1.37, 16.47)	None	None
Pancreatic cancer		OR (95% CI)		OR (95% CI)		OR (95% CI)		OR (95% CI)
Pancreatic cancer	None	None	None	None	None	None	None	None

Abbreviations: : study numbers.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.